Table 1. Antibacterial Activity of Compounds 11, 12, 19, 22, and 24 against Clinical MSSA and MRSA Strains.

| minimum
inhibitory concentration (μg/mL) |
||||||||
|---|---|---|---|---|---|---|---|---|
| MSSAa | MRSAb |
|||||||
| compd | M056 | M013 | N043 | C217 | Y069 | L166 | Z234 | 4N216 |
| 11 | 1–2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 19 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.5 |
| 22 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 24 | 1 | 4 | 4 | 4 | 4 | 4 | 4 | 0.5–1 |
| vancomycin | 2 | ≤0.5 | 1 | 1 | 1 | 2 | 1 | 1 |
Clinical MSSA strain M056.
Clinical MRSA strains M013, N043, C217, Y069, L166, Z234, and 4N216.